Apotex Health Corp.

APOTEX HEALTH CORP.'s next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, APOTEX HEALTH CORP. has 228.50M shares outstanding.

As of June 30, 2026, APOTEX HEALTH CORP. maintains a current ratio of 1.77, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 863.10, indicating elevated leverage, while an interest coverage ratio of 2.00 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 96,123.02 in revenue per employee across its workforce of 6,216.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, APOTEX HEALTH CORP. recorded 17.77M in income tax expense.

These figures cover the twelve months ended June 30, 2026.

As of June 30, 2026, APOTEX HEALTH CORP. holds 182.33M in cash and equivalents against 2.13B in total debt, resulting in a net debt position of 1.53B. Total book value stands at 246.75M, with working capital of 756.89M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026. After subtracting -43.46M in capital expenditures, free cash flow totaled -22.81M - equivalent to -0.11 per share.

Over the twelve months ended June 30, 2026, APOTEX HEALTH CORP. posted a gross margin of 49.67, reflecting its pricing power and cost economics. The operating margin of 10.22 and net profit margin of -4.52 provide insight into operational efficiency.